Skip to main content
SpringerLink
Log in

Medical comorbidity of binge eating disorder: response

  • Letter to the Editor
  • Published:
Eating and Weight Disorders - Studies on Anorexia, Bulimia and Obesity Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Dakanalis A, Clerici M (2017) The nature of the association between binge-eating severity and metabolic syndrome. Eat Weight Disord. doi:10.1007/s40519-017-0386-9

    Article  Google Scholar 

  2. Succurro E, Segura-Garcia C, Ruffo M et al (2015) Obese patients with a binge eating disorder have an unfavorable metabolic and inflammatory profile. Med (Baltimore) 94:e2098. doi:10.1097/MD.0000000000002098

    Article  CAS  Google Scholar 

  3. Tanofsky-Kraff M, Shomaker LB, Stern EA et al (2012) Children’s binge eating and development of metabolic syndrome. Int J Obes (Lond) 36:956–962. doi:10.1038/ijo.2011.259

    Article  CAS  Google Scholar 

  4. Hudson JI, Lalonde JK, Coit CE et al (2010) Longitudinal study of the diagnosis of components of the metabolic syndrome in individuals with binge-eating disorder. Am J Clin Nutr 91:1568–1573. doi:10.3945/ajcn.2010.29203

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. O’Neill S, O’Driscoll L (2015) Metabolic syndrome: a closer look at the growing epidemic and its associated pathologies. Obes Rev 16:1–12. doi:10.1111/obr.12229

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Lindner Center of HOPE, Mason, USA

    Pablo Olguin, Manuel Fuentes, Guillermo Gabler, Anna I. Guerdjikova, Paul E. Keck Jr. & Susan L. McElroy

Authors
  1. Pablo Olguin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Manuel Fuentes
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Guillermo Gabler
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Anna I. Guerdjikova
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Paul E. Keck Jr.
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Susan L. McElroy
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Anna I. Guerdjikova.

Ethics declarations

Conflict of interest

Drs. Olguin, Fuentes and Gabler have no conflicts of interest to disclose. Dr. McElroy is a consultant to or member of the scientific advisory boards of Bracket, F. Hoffmann-La Roche Ltd., MedAvante, Myriad, Naurex, Novo Nordisk, Shire, and Sunovion. She is a principal or co-investigator on studies sponsored by the Alkermes, Forest, Marriott Foundation, National Institute of Mental Health, Naurex, Orexigen Therapeutics, Inc., Shire, Sunovion, and Takeda Pharmaceutical Company Ltd. She is also an inventor on United States Patent No. 6,323,236 B2, Use of Sulfamate Derivatives for Treating Impulse Control Disorders, and along with the patent’s assignee, University of Cincinnati, Cincinnati, Ohio, has received payments from Johnson & Johnson, which has exclusive rights under the patent. Dr. Keck is employed by the University of Cincinnati College of Medicine and University of Cincinnati Physicians. Dr. Keck is presently or has been in the past year a principal or co-investigator on research studies sponsored by: Cephalon, Marriott Foundation, National Institute of Mental Health (NIMH), Shire. Dr. Keck has been reimbursed for consulting to: 2014: Shire, Supernus, Otsuka, ProPhase, Merck. Dr. Paul E. Keck, Jr. is a co-inventor on United States Patent No. 6,387,956: Shapira NA, Goldsmith TD, Keck, PE Jr. (University of Cincinnati) Methods of treating obsessive-compulsive spectrum disorder comprises the step of administering an effective amount of tramadol to an individual. Filed March 25, 1999; approved May 14, 2002. Dr. Keck has received no financial gain from this patent. Dr. Guerdjikova is employed by the University of Cincinnati College of Medicine and is a consultant for Bracket.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Olguin, P., Fuentes, M., Gabler, G. et al. Medical comorbidity of binge eating disorder: response. Eat Weight Disord 22, 725–726 (2017). https://doi.org/10.1007/s40519-017-0398-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40519-017-0398-5

Search

Navigation